Welcome to our dedicated page for KALA BIO news (Ticker: KALA), a resource for investors and traders seeking the latest updates and insights on KALA BIO stock.
KALA BIO, Inc. develops a dual strategy that combines a clinical-stage biologics pipeline for rare and severe eye diseases with an on-premises artificial intelligence infrastructure platform for biotechnology and pharmaceutical clients. Company updates cover the MSC-S platform, the KPI-012 clinical program, Researgency.ai, and the Bionic Intelligence Research Agent for secure research, clinical, regulatory, and data-workflow applications.
News also addresses capital-structure actions and corporate-status developments, including registered equity offerings, debt settlement, Nasdaq listing matters, governance changes, and the completed 1-for-50 reverse stock split of KALA common stock.
Kala Pharmaceuticals (NASDAQ:KALA) announced on August 18, 2021, the granting of non-statutory stock options to eight new employees as inducement awards outside its 2017 Equity Incentive Plan, in compliance with NASDAQ Listing Rule 5635(c)(4). A total of 78,000 stock options were granted at an exercise price of $3.03 per share, the closing price on the grant date. The options have a ten-year term, vesting over four years, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter, contingent upon continued employment.
Kala Pharmaceuticals reported a 93% increase in EYSUVIS prescriptions in Q2 2021, totaling 15,632 prescriptions. The company achieved $3.1 million in net revenue, driven by $1.7 million from EYSUVIS and $1.4 million from INVELTYS. Coverage for EYSUVIS now extends to over 96 million lives, enhancing market access. However, the operating loss widened to $29 million, and the net loss reached $36.5 million or $0.57 per share, compared to a loss of $23.3 million in Q2 2020. Cash reserves were reported at $149.6 million.
Kala Pharmaceuticals (NASDAQ: KALA) announced its participation in two virtual healthcare investor conferences in August 2021. On August 11, COO Todd Bazemore will discuss next-generation ophthalmology treatments, focusing on dry eye and AMD at the Wedbush PacGrow Healthcare Virtual Conference. On August 17, a pre-recorded presentation will be available, followed by a panel featuring CMO Kim Brazzell discussing emerging therapeutics for dry eye disease. Access to the events can be found on the Kala website.
Kala Pharmaceuticals (NASDAQ:KALA), a biopharmaceutical firm specializing in ocular therapies, will report its second quarter 2021 financial results on August 5, 2021. The company will also host a conference call at 8:00 a.m. ET to discuss the results and provide a business update. Kala's products include EYSUVIS for dry eye disease and INVELTYS for post-operative inflammation. The company leverages its proprietary AMPPLIFY mucus-penetrating particle technology to enhance drug delivery.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) announced the granting of non-statutory stock options to 16 new employees as inducement awards outside its 2017 Equity Incentive Plan. A total of 92,000 stock options were granted on July 15, 2021, with an exercise price of $4.01 per share, reflecting the closing price on that date. These options will vest over four years, with 25% vesting after the first year. This move is part of the company's strategy to attract and retain talent in its ongoing development of innovative ocular therapies.
Kala Pharmaceuticals (NASDAQ: KALA) announced the grant of non-statutory stock options to five new employees, totaling 64,500 shares. This award was made outside the 2017 Equity Incentive Plan in compliance with NASDAQ Listing Rule 5635(c)(4). The options, which vest over four years, were approved by the Compensation Committee and have an exercise price of $5.70 per share, reflecting the closing stock price on June 15, 2021. This move is aimed at incentivizing new hires as the company continues its focus on developing innovative therapies for eye diseases.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) announced that OptumRx, a major pharmacy benefit manager in the U.S., has included EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% on its commercial formularies, effective May 21, 2021. This addition allows more than 88 million people with commercial health insurance access to EYSUVIS, furthering Kala's goal of widespread market access. EYSUVIS, approved by the FDA in October 2020, is the first prescription therapy specifically for short-term dry eye disease treatment. The company aims to expand payer coverage through ongoing efforts with health plans.
Kala Pharmaceuticals (NASDAQ: KALA) will present at the Jefferies 2021 Virtual Healthcare Conference. The management team is scheduled for a fireside chat on June 3, 2021, at 10:00 am ET. Investors can access the live webcast and the archived recording through the Events section of the Kala website.
Kala focuses on innovative therapies for eye diseases, utilizing its AMPPLIFY® technology. Key products include EYSUVIS® for dry eye treatment and INVELTYS® for post-operative inflammation. The company also has a pipeline targeting unmet medical needs in ocular health.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company specializing in innovative eye disease therapies, will present at the BofA Securities 2021 Healthcare Conference. The management team is set to participate in a Fireside Chat on May 13, 2021, at 4:15 pm ET. Investors can access the live webcast and a recording afterward via the 'Events' section of the Kala website. The company's products include EYSUVIS® and INVELTYS®, which utilize AMPPLIFY® technology, addressing dry eye disease and post-operative inflammation.
Kala Pharmaceuticals (NASDAQ:KALA) reported its Q1 2021 financial results, highlighting a net loss of $30.4 million or $0.49 per share, versus a $22 million loss in Q1 2020. Product revenues reached $3.3 million, driven by EYSUVIS and INVELTYS sales. The company has secured coverage for approximately 43% of commercial lives and plans to expand its sales force from 91 to 125 by year-end. A new credit facility of up to $125 million was established to extend cash runway for at least two years. The company continues to progress its pipeline for treating eye diseases.